Martin Egli

Vanderbilt scientist Houra Merrikh led a team of researchers who discovered the first evolution-resistant chemical compound that prevents drug resistance development in bacteria. The compound is also a drug development platform that targets antimicrobial resistance during treatment of infections with antibiotics and evolution in general, Merrikh said. Read More

The World Health Organization ranks antimicrobial resistance as one of the top ten global health risks. Vanderbilt researchers led by Houra Merrikh identified the first anti-evolution compound that targets AMR during treatment of infections with antibiotics. Read More

For his outstanding achievements, including investigations directed at nucleic acid structure, DNA bypass polymerases and the circadian clock, Martin Egli has been elected to the European Academy of Sciences and Arts. The academy is dedicated to innovative research, interdisciplinary and transnational collaboration.  Read More

Vanderbilt researchers report a structure of a human metabolic enzyme bound to its substrate 17alpha-hydroxyprogesterone. Read More

An enzyme that builds DNA is able to insert the wrong building blocks, which could generate mutations. Read More

Studies of a human polymerase that replicates DNA have provided a complete kinetic and structural framework for understanding how the enzyme accurately bypasses DNA damage. Read More

Researchers have determined how a DNA lesion caused by exposure to chemicals may spark cancer formation. Read More

Understanding how an environmental hazard damages DNA may shed light on processes of tumor formation. Read More

Structural studies are providing insight to how aflatoxin – a toxin produced by fungi – contributes to cancer development. Read More

Modifying a form of RNAs may improve their efficacy for research and medical uses. Read More